All results
8 results for phase 2 multi center double blind randomized dose ranging placebo controlled study
-
Edgewise-210
The LYNX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics and biomarkers in children with Duchenne muscular dystrophy including a…
- Ages
- 4 Years - 9 Years
- Sexes
- Male
-
Protocol TN-28
A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of…
- Ages
- 12 Years - 34 Years
- Sexes
- All
-
PROTECT Extension Study
The purpose of this non-interventional extension study is to continue to collect long-term safety and other clinical data for an additional 42 months in…
- Ages
- 9 Years - 18 Years
- Sexes
- All
-
Efficacy and Safety of AMG 570 in Subjects With Active SLE
The purpose of this study is to determine if Rozibafusp Alfa could be a useful therapeutic agent in the current treatment landscape where subjects with SLE…
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
IMPALA-2
160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for…
- Ages
- 18 Years - N/A
- Sexes
- All
-
TN-31 JAKPOT T1D
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and…
- Ages
- 12 Years - 35 Years
- Sexes
- All
-
GCAptAIN
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell…
- Ages
- 50 Years - N/A
- Sexes
- All
-
Mino-Lok
This is a Phase 3, multi-center, randomized, open-label, assess-blind study to determine the efficacy and safety of MLT, a novel antibiotic lock therapy that…
- Ages
- 12 Years - N/A
- Sexes
- All